Vivace Therapeutics, Inc., San Mateo, California.
Institute of Pediatrics, Children's Hospital of Fudan University, and the Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Shanghai Medical College of Fudan University, Shanghai, China.
Mol Cancer Ther. 2021 Jun;20(6):986-998. doi: 10.1158/1535-7163.MCT-20-0717. Epub 2021 Apr 13.
Mutations in the neurofibromatosis type 2 () gene that limit or abrogate expression of functional Merlin are common in malignant mesothelioma. Merlin activates the Hippo pathway to suppress nuclear translocation of YAP and TAZ, the major effectors of the pathway that associate with the TEAD transcription factors in the nucleus and promote expression of genes involved in cell proliferation and survival. In this article, we describe the discovery of compounds that selectively inhibit YAP/TAZ-TEAD promoted gene transcription, block TEAD auto-palmitoylation, and disrupt interaction between YAP/TAZ and TEAD. Optimization led to potent analogs with excellent oral bioavailability and pharmacokinetics that selectively inhibit -deficient mesothelioma cell proliferation and growth of subcutaneous tumor xenografts These highly potent and selective TEAD inhibitors provide a way to target the Hippo-YAP pathway, which thus far has been undruggable and is dysregulated frequently in malignant mesothelioma and in other YAP-driven cancers and diseases.
神经纤维瘤病 2 型 () 基因突变限制或消除功能性 Merlin 的表达在恶性间皮瘤中很常见。 Merlin 激活 Hippo 通路,抑制 YAP 和 TAZ 的核转位,YAP 和 TAZ 是该通路的主要效应物,与核内的 TEAD 转录因子结合,并促进与细胞增殖和存活相关的基因表达。在本文中,我们描述了发现选择性抑制 YAP/TAZ-TEAD 促进基因转录、阻断 TEAD 自动棕榈酰化、破坏 YAP/TAZ 和 TEAD 之间相互作用的化合物。优化导致具有良好口服生物利用度和药代动力学的有效类似物,选择性抑制 -缺陷性间皮瘤细胞增殖和皮下肿瘤异种移植物生长。这些高效且选择性的 TEAD 抑制剂为靶向 Hippo-YAP 通路提供了一种方法,迄今为止,该通路一直无法成药,并且在恶性间皮瘤以及其他 YAP 驱动的癌症和疾病中经常失调。